Alert detail
FDA Approval: TERLIVAZ (TERLIPRESSIN) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA022231Specialty: GastroenterologyAdded: 6/13/2026Effective: 2022-09-14billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.